Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk

Inclusion Criteria: * Adults \>18 years * Diagnosis of heart failure (any aetiology or left ventricular ejection fraction classification), any timeframe * Currently prescribed ≥40 mg/day of furosemide (or equivalent loop diuretic) for at least one month. * Heart failure hospital admission and moderate or severe leg oedema in the previous 12 months. * Lives in the UK, with a home environment suitable for installation of the Heartfelt device. Exclusion Criteria: * Amputation of both feet * Bed-bound for more than 20h per 24h period * Bandages to lower limbs every day * Regular wheelchair user inside their home * No fixed abode * Participation in another interventional trial that may interfere with endpoints * Life expectancy \<6 months, in the opinion of the investigator * Inability to provide informed consent due to cognitive impairment * Language barriers that preclude understanding of trial procedures (unless translation resources are available in relevant language) * Inability to install the device (even with assistance) allowing at least 6 months of data capture by the end of the study. * Patients with severe aortic stenosis or awaiting a heart procedure or surgery * Patient with end stage renal disease (eGFR \<20) * Pregnancy or lack of contraceptive measures if of child-bearing potential